

G1 H,Me

G2 X,NO2

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 16:19:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -          7 TO ITERATE

100.0% PROCESSED      7 ITERATIONS           6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:    7 TO      298
PROJECTED ANSWERS:       6 TO      266
```

L2 6 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 16:19:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -          62 TO ITERATE

100.0% PROCESSED      62 ITERATIONS          37 ANSWERS
SEARCH TIME: 00.00.01
```

L3 37 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS           SINCE FILE        TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          178.36          178.57
```

```
FILE 'CAPLUS' ENTERED AT 16:19:31 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Apr 2008 VOL 148 ISS 14
FILE LAST UPDATED: 2 Apr 2008 (20080402/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 2 L3


=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:684674 CAPLUS
 DOCUMENT NUMBER: 147:301126
 TITLE: 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol
 1,1-dioxides
 AUTHOR(S): as novel and selective CXCR2 antagonists
 Wang, Yonghui; Busch-Petersen, Jakob; Wang, Feng; Ma,
 Lanping; Fu, Wei; Kerns, Jeffrey K.; Jin, Jian;
 Falovich, Michael R.; Shen, Jing-Kang; Burman,
 Miriam;
 Foley, James J.; Schmidt, Dulcie B.; Hunberger,
 Gerald E.; Sarau, Henry M.; Widdowson, Katherine L.
 CORPORATE SOURCE: Discovery Medicinal Chemistry, Molecular Discovery
 Research, GlaxoSmithKline, Collegeville, PA, 19426,
 USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007),
 17(14), 3864-3867
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:301126
 AB A series of 3-arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides were prepared and shown to be novel and selective antagonists of the CXCR2 receptor. Synthesis, structure and activity relationships, selectivity, and some developability properties are described.
 IT 820214-10-6 947159-66-2 947159-67-3
 947159-68-4
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (preparation of 3-arylamino-2H-1,2,4-benzothiadiazin-5-ol
 1,1-dioxides as
 CXCR2 antagonists)
 RN 820214-10-6 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-(cyclopentylamino)-,
 1,1-dioxide
 (CA INDEX NAME)




RN 947159-66-2 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(phenylmethyl)amino]-,
 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 947159-67-3 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol,
 7-chloro-3-[(2-chlorophenyl)methyl]amino)-,
 1,1-dioxide (CA INDEX NAME)




RN 947159-68-4 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(1R)-1-methylpropyl]amino)-,
 1,1-dioxide (CA INDEX NAME)

Absolute stereochemistry.




IT 947159-64-0P 947159-65-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-arylamino-2H-1,2,4-benzothiadiazin-5-ol
 1,1-dioxides as
 CXCR2 antagonists)
 RN 947159-64-0 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 4H-1,2,4-Benzothiadiazin-3-amine, 7-chloro-N-(2-chloro-3-fluorophenyl)-5-methoxy-, 1,1-dioxide (CA INDEX NAME)




RN 947159-65-1 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3-amine, N-(2-bromophenyl)-5-methoxy-7-nitro-,
 1,1-dioxide (CA INDEX NAME)




IT 820214-07-1P 820214-12-8P 820214-14-0P
 820214-15-1P 947159-39-9P 947159-40-2P
 947159-41-3P 947159-42-4P 947159-43-5P
 947159-44-6P 947159-45-7P 947159-46-8P
 947159-47-9P 947159-48-0P 947159-49-1P
 947159-50-4P 947159-51-5P 947159-53-7P
 947159-54-8P 947159-55-9P 947159-56-0P
 947159-57-1P 947159-58-2P 947159-59-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation)
 (preparation of 3-arylamino-2H-1,2,4-benzothiadiazin-5-ol
 1,1-dioxides as
 CXCR2 antagonists)
 RN 820214-07-1 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-chlorophenyl)amino]-,
 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 820214-12-8 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-chlorophenyl)amino]-7-nitro-,
 1,1-dioxide (CA INDEX NAME)




RN 820214-14-0 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromophenyl)amino]-7-nitro-,
 1,1-dioxide (CA INDEX NAME)




RN 820214-15-1 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 7-nitro-3-[(2-phenoxyphenyl)amino]-,
 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



RN 947159-39-9 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-(phenylamino)-, 1,1-dioxide
 (CA INDEX NAME)




RN 947159-40-2 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-fluorophenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




RN 947159-41-3 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947159-42-4 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(3-bromophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-43-5 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(4-bromophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-44-6 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-chloro-3-fluorophenyl)amino]-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947159-45-7 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromo-4-fluorophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-46-8 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromo-5-fluorophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-47-9 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromo-6-fluorophenyl)amino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947159-48-0 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-methylphenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




RN 947159-49-1 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(1,1'-biphenyl)-2-ylamino]-7-chloro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-50-4 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-methoxyphenyl)amino]-, 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



RN 947159-51-5 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-phenoxyphenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




RN 947159-53-7 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-(trifluoromethyl)phenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




RN 947159-54-8 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-(trifluoromethoxy)phenyl)amino]-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947159-55-9 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-(4-nmorpholinyl)phenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




RN 947159-56-0 CAPLUS
 CN Ethanone, 1-[2-[(7-chloro-5-hydroxy-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)amino]phenyl]- (CA INDEX NAME)




RN 947159-57-1 CAPLUS
 CN Benzoic acid, 2-[(7-chloro-5-hydroxy-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)amino]- (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947159-58-2 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromophenyl)amino]-7-fluoro-, 1,1-dioxide (CA INDEX NAME)




RN 947159-59-3 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-bromo-3-[(2-bromophenyl)amino]-, 1,1-dioxide (CA INDEX NAME)




IT 820214-08-2P 820214-09-3P 947159-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-arylamino-2H-1,2,4-benzothiadiazin-5-ol
 1,1-dioxides as
 CXCR2 antagonists)
 RN 820214-08-2 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3(4H)-one, 7-chloro-5-methoxy-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 820214-09-3 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3-amine, 7-chloro-N-(2-chlorophenyl)-5-methoxy-, 1,1-dioxide (CA INDEX NAME)



RN 947159-63-9 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-, 7-chloro-5-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl ester (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:14159 CAPLUS
 DOCUMENT NUMBER: 142:107422
 TITLE: IL-8 receptor antagonists of substituted 3-phenylamino-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides
 INVENTOR(S): Busch-Petersen, Jakob; Fu, Wei; Kerns, Jeffrey K.; Palovich, Michael R.; Widdowson, Katherine Louise
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 24 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000231	A2	20050106	WO 2004-US17892	20040604
WO 2005000231	A3	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, IO, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, SN, TD, TG				
EP 163159	A2	20060308	EP 2004-754490	20040604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CT, TK, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527201	T	20061130	JP 2006-515230	20040604
US 20060122173	A1	20060608	US 2005-559154	20051205
PRIORITY APPLN. INFO.:			US 2003-476656P	P 20030606
			WO 2004-US17892	W 20040604

AB This invention relates to novel compds. of substituted 3-phenylamino-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides and compns. thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). For example, 7-chloro-3-[(2-chlorophenyl)amino]-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxide was synthesized and was found to be able to prevent elastase release from human neutrophils and can be used in brain injury.
 IT 820214-08-2P 820214-09-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep of IL-8 receptor antagonists of substituted 3-phenylamino-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides for treatment of inflammations and CNS disorders and other chemokine related disorders)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 820214-10-6 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-(cyclopentylamino)-, 1,1-dioxide (CA INDEX NAME)




RN 820214-11-7 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2,3-dichlorophenyl)amino]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 820214-12-8 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-chlorophenyl)amino]-7-nitro-, 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 820214-08-2 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3(4H)-one, 7-chloro-5-methoxy-, 1,1-dioxide (CA INDEX NAME)



RN 820214-09-3 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3-amine, 7-chloro-N-(2-chlorophenyl)-5-methoxy-, 1,1-dioxide (CA INDEX NAME)




IT 820214-07-1P 820214-10-6P 820214-11-7P
 820214-12-6P 820214-13-9P 820214-14-0P
 820214-15-1P 820214-16-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep of IL-8 receptor antagonists of substituted 3-phenylamino-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides for treatment of inflammations and CNS disorders and other chemokine related disorders)

RN 820214-07-1 CAPLUS
 CN 4H-1,2,4-Benzothiadiazin-5-ol, 7-chloro-3-[(2-chlorophenyl)amino]-, 1,1-dioxide (CA INDEX NAME)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 820214-13-9 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3-amine, N-(2-chlorophenyl)-5-methoxy-7-nitro-, 1,1-dioxide (CA INDEX NAME)




RN 820214-14-0 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 3-[(2-bromophenyl)amino]-7-nitro-, 1,1-dioxide (CA INDEX NAME)





RN 820214-15-1 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol, 7-nitro-3-[(2-phenoxyphenyl)amino]-, 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



RN 820214-16-2 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-5-ol,
 3-[(2-chloro-3-fluorophenyl)amino]-7-nitro-,
 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 INDEX NAME)

IT 820214-08-2DP, reaction products with triflic anhydride
 820214-19-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn of IL-8 receptor antagonists of substituted 3-phenylamino-4H-
 1,2,4-benzothiadiazin-5-ol 1,1-dioxides for treatment of inflammations
 and CNS disorders and other chemokine related disorders)
 RN 820214-08-2 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3(4H)-one, 7-chloro-5-methoxy-, 1,1-dioxide (CA
 INDEX NAME)



RN 820214-19-5 CAPLUS
 CN 2H-1,2,4-Benzothiadiazin-3(4H)-one, 5-methoxy-7-nitro-, 1,1-dioxide (CA